Adagio Medical Holdings, Inc - Common Stock (ADGM)
1.2000
-0.5800 (-32.58%)
NASDAQ · Last Trade: Apr 21st, 5:17 PM EDT
Detailed Quote
Previous Close
1.780
Open
1.310
Bid
1.180
Ask
1.200
Day's Range
1.170 - 1.490
52 Week Range
0.6325 - 9.340
Volume
2,144,522
Market Cap
-
PE Ratio (TTM)
-
EPS (TTM)
-
Dividend & Yield
N/A (N/A)
1 Month Average Volume
5,807,139
Chart
About Adagio Medical Holdings, Inc - Common Stock (ADGM)
Adagio Medical Holdings, Inc. is a healthcare company focused on developing innovative medical technologies to enhance patient outcomes in the treatment of various medical conditions. The company specializes in creating advanced therapeutic solutions that utilize cutting-edge technology, aiming to improve the efficacy and safety of treatments in fields such as cardiology and beyond. By advancing its proprietary devices and systems, Adagio Medical is committed to delivering impactful healthcare solutions that address unmet clinical needs and improve the quality of life for patients. Read More
Looking for insights into the US markets in the middle of the day on Monday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
The company said the FDA’s nod validates its proprietary system as a "potentially unique solution for the large, underserved population of patients suffering from ventricular tachycardia."
Health In Tech (NASDAQ: HIT), a fast-growing AI-powered insurtech, reported Q1 2025 revenue of $8.0M, up 56% YoY , exceeding estimates. Its platform now supports 24,307 enrolled employees , reflecting a 16.8% increase in usage and strong market penetration.
Adagio Medical shares are trading higher by 142% during Thursday's session. The FDA granted Breakthrough Device Designation for the vCLAS cryoablation system.
Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that it has received Breakthrough Device designation from the U.S. Food and Drug Administration (“FDA”) for its vCLASTM Cryoablation System for the treatment of drug-refractory, recurrent, sustained monomorphic ventricular tachycardia (“VT”) in patients with ischemic or non-ischemic structural heart disease. Adagio’s vCLASTM Cryoablation System, which is currently the subject of an Investigational Device Exemption (“IDE”) study called FULCRUM-VT, is a purpose-built system using the Company’s proprietary Ultra-Low Temperature Cryoablation (“ULTC”) technology and is designed to improve the safety and effectiveness of VT ablations and patient outcomes.
Adagio Medical (Nasdaq: ADGM), a leading innovator in catheter ablation technologies for treatment of cardiac arrhythmias, is pleased to announce the appointment of Deborah Kaster as Chief Business Officer (CBO). Kaster brings more than 25 years of leadership experience in strategy, mergers and acquisitions, corporate finance, investor relations and strategic communications in the medical technology sector.
Adagio Medical Holdings, Inc. (Nasdaq: ADGM), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today reported financial results for the fourth quarter and full year ended December 31, 2024.
Adagio Medical Holdings, Inc. (Nasdaq: ADGM; the “Company”), a leading innovator in catheter ablation technologies, provided updates today on the progress in its streamlined focus on leadership in ventricular tachycardia (“VT”) solutions.
Adagio Medical Holdings, Inc. (Nasdaq: ADGM; the “Company”), a leading innovator in catheter ablation technologies for treatment of cardiac arrhythmias, today announced a corporate restructuring and realignment of resources to prioritize its FULCRUM-VT US pivotal investigational device exemption (“Pivotal IDE”) clinical trial activities and its new product design optimization program. “After a comprehensive strategic review, we are doubling down on the priorities that will drive the most meaningful impact for physicians, patients, and shareholders,” said Todd Usen, the Chief Executive Officer of Adagio. “Our resources are now focused on the completion of the FULCRUM-VT Pivotal IDE trial and subsequent premarket approval of the VT Cryoablation System with vCLAS™ catheter from the U.S. Food and Drug Administration (“FDA”). With over 35% enrollment complete, we, along with our physicians, are very encouraged by the system’s performance and early outcomes. In addition, we will dedicate the appropriate resources to our product design optimization program, which allows us to design, iterate and innovate more efficiently. We believe that this focused approach is crucial to position Adagio as a leader in ventricular tachycardia solutions, which has been a historically underserved market.”
Adagio Medical Holdings, Inc. (Nasdaq: ADGM; the “Company”), a leading innovator in catheter ablation technologies for treatment of cardiac arrhythmias, today announced that management will be attending TD Cowen's 45th Annual Health Care Conference on Tuesday, March 4, 2025, at the Marriott Copley Place in Boston, MA.
